Bristol-Myers Squibb and Pfizer report positive cardiovascular data from apixaban (Eliquis).
Bristol-Myers Squibb and Pfizer recently announced that they will be presenting 8 abstracts at the American College of Cardiology (ACC) 66th Annual Scientific Session related to companies’ alliance to develop and commercialize apixaban (Eliquis).
The companies will present findings from the phase 3 ARTISTOTLE trial, as part of the ACROPOLIS program, which focuses on real-world data, according to a press release.
The ACROPOLIS program was designed to inform healthcare decision makers, including providers and payers, about using apixaban in a real-world setting. The program includes analyses from more than 10 databases that include medical records, insurance claims, and national health data systems, Bristol-Myers Squibb reported.
The studies presented will focus on the use of apixaban to improve cardiovascular health in different groups of patients. The abstracts will demonstrate both Bristol-Myers Squibb and Pfizer’s commitment to exploring the use of direct oral anticoagulants, such as apixaban, in clinical practice.
“During ACC, the Bristol-Myers Squibb and Pfizer Alliance will share several analyses that delve deeper into the robust data generated from the ARISTOTLE study,” said Christoph Koenen, MD, MBA, vice president, development lead, Eliquis at Bristol-Myers Squibb. “Through continued analyses and support of the ARISTOTLE trial, we can examine topics such as outcomes for patients with different comorbidities and the potential treatment effects of interacting drugs, which expands our scientific understanding.”
Researchers will present data from the ARISTOTLE trial, which explored the efficacy and safety of apixaban versus warfarin for the prevention of stroke of systemic embolism.
Apixaban is an oral selective Factor Xa inhibitor, which is a blood clotting protein, and has been observed to reduce thombin generation and blood clots, according to the press release. Apixaban has been approved to lower the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; prophylaxis of deep vein thrombosis; treatment of deep vein thrombosis and pulmonary embolism, and prevent recurrence of the conditions, according to the release.
“As physicians evaluate options for reducing stroke risk in patients with non-valvular atrial fibrillation, they often face questions about the effectiveness and safety of therapies in day-to-day practice,” said Rory O’Connor, MD, chief medical officer, Pfizer Innovative Health. “Real-world data analyses allow us to explore the usage of Eliquis and anticoagulants across various geographies and subgroups of patients. Alongside clinical data, the real-world data analyses we are presenting during ACC have the potential to help healthcare providers make more informed decisions along with their patients.”